Bevacizumab plus interferon alpha in patients with metastatic renal cell carcinoma [0.03%]
贝伐单抗联合干扰素α治疗转移性肾细胞癌患者
Przemyslaw Twardowski,Robert A Figlin
Przemyslaw Twardowski
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer [0.03%]
结直肠癌患者化疗相关毒副反应的预测因素分析
Bruno Vincenzi,Gaia Schiavon,Francesco Pantano et al.
Bruno Vincenzi et al.
Colorectal cancer represents a major health problem in the Western world. Many drugs have been used for the treatment of this disease, but there is little information about how predictive factors can be used to aid treatment response and an...
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma [0.03%]
来那度胺联合地塞米松治疗复发或难治多发性骨髓瘤患者的疗效较好
Nikhil C Munshi,Constantine Mitsiades,Paul G Richardson et al.
Nikhil C Munshi et al.
Grace Suh,Anas Younes
Grace Suh
Mechanisms of disease: temozolomide and glioblastoma--look to the future [0.03%]
疾病的机制：替莫唑胺和胶质母细胞瘤—展望未来
Maciej M Mrugala,Marc C Chamberlain
Maciej M Mrugala
Glioblastoma is both the most common and most aggressive primary brain tumor. Until recently, the standard of care involved maximal safe surgical resection followed by radiation therapy with or without nitrosourea-based chemotherapy. In 200...
Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas [0.03%]
疾病机制：干细胞在胶质瘤的生物学和治疗中的作用
Jörg Dietrich,Jaime Imitola,Santosh Kesari
Jörg Dietrich
The study of neural stem cell and progenitor cell biology has improved our understanding of the biology of brain tumors in a developmental context. Recent work has demonstrated that brain tumors may harbor small subpopulations of cells that...
David Kelsen
David Kelsen
Jay S Loeffler
Jay S Loeffler
Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer [0.03%]
帕尼单抗：治疗结直肠癌的一种很有前景的药物
Max Mano,Yves Humblet
Max Mano
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in Western countries. Despite the progress achieved with the introduction of new cytotoxic agents, CRC recurrence rates for patients with resected stage II and/...
Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer [0.03%]
多重临床检测确定ER阳性乳腺癌最佳治疗策略的优势
Henrik J Ditzel,Maria B Lyng
Henrik J Ditzel